Literature DB >> 9528900

The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Italian CD4 Quality Control Group.

F Pandolfi1, C Alario, E Girardi, L Rava, G Ippolito, A Kunkl, F Aiuti.   

Abstract

We report on the experience of establishing a national network for a quality control programme in evaluating CD4 cell counts in most Italian centres involved in the care of patients with HIV disease. The 68 centres were divided according to their geographical location into eight groups, and twice a year (tests A and B) they received three coded whole blood samples (two were replicates of the same sample) obtained from two informed HIV+ patients, one with CD4 counts/mm3 expected to be < 200 and one with values > 300. The medians of the determinations performed by the labs involved in each of the eight areas were taken as the 'true' values for each sample. Unsatisfactory performances for percentage of CD4 cells were identified as a CD4 analysis with residual values > or = +/- 5% and with deviates > or = +/- 2. For absolute numbers of CD4 cells, an unsatisfactory performance was defined as CD4 counts with residual > +/- 100 CD4 cells/mm3 and with deviates > or = +/- 2. The residual value is the CD4 value reported by each lab minus the median value. The deviate is the residual divided by the modified interquartile range (IQR x 0.75). Most of the centres provided reliable results. However, some labs failed to provide satisfactory results for percentages (6.25% of the tested labs for test A and 6.17% for test B) or absolute numbers (16.25% test A and 12.34% test B). Only 3.7% of the labs gave unsatisfactory results in both tests. Four of the unsatisfactory results from the two tests gave an error in absolute numbers > +/- 200 CD4 cells/mm3. Our data suggest that most Italian labs provide reliable results in evaluating the numbers of CD4 cells in HIV-1+ samples, but the importance of running a quality control programme is highlighted by our experience with those centres which provide unsatisfactory data which may lead to incorrect classification of the patients or assessment of treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9528900      PMCID: PMC1904887          DOI: 10.1046/j.1365-2249.1998.00520.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Lymphocyte subset analysis to predict progression to AIDS in a cohort of homosexual men in San Francisco.

Authors:  D P Stites; A R Moss; P Bacchetti; D Osmond; T M McHugh; Y J Wang; S Hebert; B Colfer
Journal:  Clin Immunol Immunopathol       Date:  1989-07

2.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men.

Authors:  B F Polk; R Fox; R Brookmeyer; S Kanchanaraksa; R Kaslow; B Visscher; C Rinaldo; J Phair
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

3.  Two-year evaluation of clinical and laboratory variables of immune function in 117 hemophiliacs seropositive or seronegative for HIV-1.

Authors:  J M Teitel; J J Freedman; M B Garvey; M Kardish
Journal:  Am J Hematol       Date:  1989-12       Impact factor: 10.047

4.  Model system evaluating fluorescein-labeled microbeads as internal standards to calibrate fluorescence intensity on flow cytometers.

Authors:  R F Vogt; G D Cross; L O Henderson; D L Phillips
Journal:  Cytometry       Date:  1989-05

5.  CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.

Authors:  H Masur; F P Ognibene; R Yarchoan; J H Shelhamer; B F Baird; W Travis; A F Suffredini; L Deyton; J A Kovacs; J Falloon
Journal:  Ann Intern Med       Date:  1989-08-01       Impact factor: 25.391

6.  Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy.

Authors:  B Brando; E Sommaruga
Journal:  Cytometry       Date:  1993

7.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use.

Authors:  J M Taylor; J L Fahey; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

8.  Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.

Authors: 
Journal:  MMWR Suppl       Date:  1989-06-16

9.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Authors:  A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  4 in total

1.  CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.

Authors:  A Giovannetti; F Ensoli; F Mazzetta; M De Cristofaro; M Pierdominici; D S Muratori; V Fiorelli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  CD4 immunophenotyping in HIV infection.

Authors:  David Barnett; Brooke Walker; Alan Landay; Thomas N Denny
Journal:  Nat Rev Microbiol       Date:  2008-11       Impact factor: 60.633

3.  Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women.

Authors:  Stephenson Musiime; Fred Muhairwe; Alfred Rutagengwa; Eugene Mutimura; Kathryn Anastos; Donald R Hoover; Shi Qiuhu; Elizaphane Munyazesa; Ivan Emile; Annette Uwineza; Ethan Cowan
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

Review 4.  A Critical Review on the Standardization and Quality Assessment of Nonfunctional Laboratory Tests Frequently Used to Identify Inborn Errors of Immunity.

Authors:  Sandro Félix Perazzio; Patricia Palmeira; Dewton Moraes-Vasconcelos; Andréia Rangel-Santos; João Bosco de Oliveira; Luis Eduardo Coelho Andrade; Magda Carneiro-Sampaio
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.